Understanding AI's Expanding Role in Drug Dis...

For consumer goods companies, the gap between the commercial plan agreed at head office and what gets executed on the shelf is one of the costliest disconnects in the business — investment goes out against activity that never happens, and revenue never arrives against activity th ...  Show more

Traditional, event-based training can't keep pace with technical skills that now shift every six to twelve months. ​ In this episode, Nicola Lyons, Senior Director of Talent Operations at Andela, breaks down why assessment-based, personalized learning is replacing one-time traini ...  Show more

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the centra ...  Show more

Shai Shen-Orr, co-founder and chief scientist at CytoReason and professor at the Technion, talks about the next frontier in healthcare: disease modeling. Shai shares how CytoReason bridges the gap between exploding biological data and actionable insight, powering smarter, faster ...  Show more

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA’s AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Rec ...  Show more

GSK’s Chief Digital and Technology Officer Shobie Ramakrishnan discusses how the company is leveraging AI and data models for vaccine development and drug discovery in this episode of Bloomberg Intelligence’s Tech Disruptors podcast. BI’s Health-Care Analyst Sam Fazeli and Techno ...  Show more